| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S Kumra, J A Frazier, L K Jacobsen, K McKenna, C T Gordon, M C Lenane, S D Hamburger, A K Smith, K E Albus, J Alaghband-Rad, J L Rapopor. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Archives of general psychiatry. vol 53. issue 12. 1997-01-10. PMID:8956674. |
in this study, the efficacy and adverse effects of clozapine and haloperidol were compared for children and adolescents with early-onset schizophrenia. |
1997-01-10 |
2023-08-12 |
Not clear |
| C VanderZwaag, M McGee, J P McEvoy, O Freudenreich, W H Wilson, T B Coope. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. The American journal of psychiatry. vol 153. issue 12. 1997-01-08. PMID:8942454. |
response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. |
1997-01-08 |
2023-08-12 |
Not clear |
| R W Buchanan, B Kirkpatrick, N Bryant, P Ball, A Breie. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. The American journal of psychiatry. vol 153. issue 12. 1997-01-08. PMID:8942462. |
fluoxetine augmentation of clozapine treatment in patients with schizophrenia. |
1997-01-08 |
2023-08-12 |
Not clear |
| D C Goff, G Tsai, D S Manoach, J Flood, D G Darby, J T Coyl. D-cycloserine added to clozapine for patients with schizophrenia. The American journal of psychiatry. vol 153. issue 12. 1997-01-08. PMID:8942463. |
d-cycloserine added to clozapine for patients with schizophrenia. |
1997-01-08 |
2023-08-12 |
Not clear |
| J A Lieberma. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. The Journal of clinical psychiatry. vol 57 Suppl 11. 1997-01-02. PMID:8941173. |
clozapine represented the first significant advance in the pharmacotherapy of schizophrenia since the introduction of conventional antipsychotic drugs in the 1950's. |
1997-01-02 |
2023-08-12 |
Not clear |
| J A Lieberma. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. The Journal of clinical psychiatry. vol 57 Suppl 11. 1997-01-02. PMID:8941173. |
despite its superior efficacy and potential to reduce substantially the morbidity of schizophrenia and improve the outcomes, of patients, clozapine has not been used on a widespread basis or as a first-line treatment due to its potential for agranulocytosis. |
1997-01-02 |
2023-08-12 |
Not clear |
| D D Mille. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 8. issue 2. 1996-12-26. PMID:8807035. |
the clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. |
1996-12-26 |
2023-08-12 |
Not clear |
| D D Mille. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 8. issue 2. 1996-12-26. PMID:8807035. |
six recent studies have examined the utility of clozapine plasma concentrations in predicting response in treatment-refractory patients with schizophrenia. |
1996-12-26 |
2023-08-12 |
Not clear |
| D D Mille. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 8. issue 2. 1996-12-26. PMID:8807035. |
thus, there is now compelling evidence that clozapine plasma concentrations may play an important role in maximizing the probability of clinical response to clozapine in treatment-refractory schizophrenia. |
1996-12-26 |
2023-08-12 |
Not clear |
| D D Mille. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists. vol 8. issue 2. 1996-12-26. PMID:8807035. |
the discussion includes guidelines regarding the clinical use of clozapine plasma concentrations in the pharmacological management of persons with treatment-refractory schizophrenia. |
1996-12-26 |
2023-08-12 |
Not clear |
| M A Fuller, G Jurjus, K Kwon, P E Konicki, G E Jaski. Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia. Journal of clinical psychopharmacology. vol 16. issue 4. 1996-12-20. PMID:8835710. |
we conclude that clozapine may be a highly effective treatment for polydipsia in patients with treatment-refractory schizophrenia. |
1996-12-20 |
2023-08-12 |
Not clear |
| R Ranjan, H Y Meltze. Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biological psychiatry. vol 40. issue 4. 1996-12-18. PMID:8871771. |
three cases of resistant psychotic depression were treated with clozapine monotherapy, an atypical antipsychotic drug effective in treatment-resistant schizophrenia and mania. |
1996-12-18 |
2023-08-12 |
Not clear |
| H Y Meltzer, P A Thompson, M A Lee, R Ranja. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 14. issue 3 Suppl. 1996-12-13. PMID:8866741. |
cognitive measures predict work function and overall outcome on clozapine as assessed by the global assessment scale and quality-of-life scale in neuroleptic--resistant schizophrenia. |
1996-12-13 |
2023-08-12 |
Not clear |
| J Gerlach, H Lublin, L Peacoc. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 14. issue 3 Suppl. 1996-12-13. PMID:8866742. |
other receptor affinities may contribute to the beneficial effect of clozapine in eps and schizophrenia. |
1996-12-13 |
2023-08-12 |
Not clear |
| R Gray, N Smedley, K Miller, S Vearnal. Health education needs of people with schizophrenia taking clozapine. Journal of clinical nursing. vol 5. issue 5. 1996-12-13. PMID:8932035. |
health education needs of people with schizophrenia taking clozapine. |
1996-12-13 |
2023-08-12 |
Not clear |
| M Poyurovsky, H Hermesh, A Weizma. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. Clinical neuropharmacology. vol 19. issue 4. 1996-12-06. PMID:8828993. |
interest in the association of obsessive-compulsive (oc) symptoms and schizophrenia has been reawakened since the introduction of clozapine for treatment of schizophrenia. |
1996-12-06 |
2023-08-12 |
Not clear |
| B Gallhofer, U Bauer, S Lis, S Krieger, H Grupp. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 6 Suppl 2. 1996-12-04. PMID:8792116. |
in view of the restrictions on the use of clozapine, it is suggested that risperidone should be more widely used in schizophrenia because it preserves cognitive function better than conventional neuroleptics and is therefore likely to allow patients to have better insight into their illness and to have better long-term quality of life expectations. |
1996-12-04 |
2023-08-12 |
Not clear |
| G Bondolfi, P Baumann, H Dufou. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 6 Suppl 2. 1996-12-04. PMID:8792117. |
risperidone, which is effective in chronic schizophrenia and has a low side effect profile and does not require routine blood monitoring, was compared with clozapine in a double-blind comparative study in 86 treatment-resistant patients. |
1996-12-04 |
2023-08-12 |
Not clear |
| K T Matsuda, M C Cho, K M Lin, M W Smith, A S Young, J A Adam. Clozapine dosage, serum levels, efficacy, and side-effect profiles: a comparison of Korean-American and Caucasian patients. Psychopharmacology bulletin. vol 32. issue 2. 1996-12-03. PMID:8783895. |
this study compares dosage, efficacy, and side-effect profiles in 17 korean-american and 17 caucasian age- and sex-matched schizophrenia or schizoaffective patients treated with clozapine. |
1996-12-03 |
2023-08-12 |
Not clear |
| H J Koponen, E Leinonen, U Lepol. Fluvoxamine increases the clozapine serum levels significantly. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 6. issue 1. 1996-12-03. PMID:8866941. |
in this case report we describe an interaction between clozapine and fluvoxamine in two physically healthy patients meeting the dsm-iiir criteria for paranoid schizophrenia. |
1996-12-03 |
2023-08-12 |
Not clear |